FDA approves Roche Amvetin and chemotherapy for treatment after initial surgical removal in women with advanced ovarian cancer

recently, the U.SFood andDrug(
FDA() approved Roche's Avastin (generic name: bevacizumab, bevamono) and chemotherapy (caplatinum y sequoia) after the combination of treatment to continue the Avastin monotherapy model, for advanced stage (stage III or IV) ovarian cancer patients after the first surgery after surgerya monoclonal antibody drug that specifically binds and inhibits the biological effects of vascular endothelial growth factors (VEGF)VEGF is a key driver of tumor angiogenesis, and angiogenesis is needed for tumor growth and diffusion (metastasis)Avastin's precise way of working allows it to be effectively combined with chemotherapy and other forms of anti-cancer treatmentAvastin inhibits tumor growth, prolongs survival, and has limited effect on chemotherapy side effectsthe approval of the relevant research, based on data from the key Phase III clinical study GOG-0218the study was a multicenter, randomized, double-blind, placebo-controlled study conducted in 1,873 previously untreated women with stage III or STAGE IV epithelial ovary, fallopian tubes, or primary peritoneal cancer, who had undergone surgery to remove the tumor as much as possibleIn the study, patients were randomly assigned to three treatment groups: chemotherapy group (caplatinum and yew alcohol), Avastin (15mg/kg) and chemotherapy combined with chemotherapy after receiving a placebo treatment group, Avastin (15 mg/kg) and chemotherapy after combined treatment continued to receive Avastin single-drug treatment group, a total of 22 coursesThe primary endpoint of thestudy was the progressionless lifetime (PFS) assessed by the researchers, and the secondary endpoint scored including total survival (OS)data showed that Avastin continued to receive a significant length of PFS in the Avastin monotherapy group (median PFS: 18.2 months vs 12.0 months, 95% CI: 0.52-0.75, p 0.0001) after combining with chemotherapy This PFS benefit is achieved using fixed duration therapy (a total of 22 courses of Avastin) currently, Avastin has become an important pillar of clinical lygo antiangiogenic therapy, with more than 2.7 million patients worldwide receiving Avastin treatment to date , Roche is currently conducting a large clinical project investigating the potential of Avastin to treat more than 50 types of tumors